QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS5-Region Domestic Shipping
What is Tesamorelin??
Tesamorelin (CAS 218949-48-9) is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH) comprising the full 44-amino acid GHRH sequence conjugated to a trans-3-hexenoic acid moiety at the N-terminus — conferring improved stability against DPP-IV degradation and enhanced GHRHr binding. Molecular formula C₂₂₁H₃₆₆N₆₈O₇₀S, MW ~5135 Da. FDA-approved as Egrifta® for HIV-associated lipodystrophy, Tesamorelin stimulates pulsatile GH release, which subsequently elevates IGF-1 and drives selective visceral fat reduction — making it the premier GHRH analog for adipose-GH axis research.
Research Applications
Visceral Adipose Research
VAT reduction via GH/IGF-1 axis, lipolysis, FFA mobilisation — lipodystrophy and metabolic syndrome models
GHRHr Signalling
GHRH receptor binding kinetics, Gs/cAMP/PKA cascade, somatotroph cell activation
Pulsatile GH Release
Authentic GHRH-driven GH pulse physiology, IGF-1 axis induction — vs. recombinant HGH
DPP-IV Stability Studies
Trans-3-hexenoic acid N-terminal modification — protease resistance vs. native GHRH and CJC-1295
Metabolic Research
Lipid metabolism, visceral fat, insulin sensitivity, body composition in GH-deficiency models
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | 218949-48-9 |
| Also Known As | Egrifta® active peptide, TH9507, TransCon GHRH analog |
| Molecular Formula | C₂₂₁H₃₆₆N₆₈O₇₀S |
| Molecular Weight | ~5135 Da |
| Peptide Type | Synthetic GHRH analog — N-terminal trans-3-hexenoic acid modification |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | -20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | 24 months unopened |
